Drug Type T-lymphocyte cell therapy |
Synonyms Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells, Anti-CD3 x Anti-Her2/neu Bispecific Antibody-Armed Activated T Cells |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 2 | US | 07 Jun 2018 | |
Adenocarcinoma of prostate | Phase 2 | US | 07 Jun 2018 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 07 Jun 2018 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 07 Jun 2018 | |
Metastatic Prostate Carcinoma | Phase 2 | US | 07 Jun 2018 | |
Metastatic Prostate Carcinoma | Phase 2 | US | 07 Jun 2018 | |
Breast Cancer | Phase 2 | US | 01 Jul 2010 | |
HER2-negative breast cancer | Phase 2 | US | 08 Mar 2010 | |
Clear cell neoplasm of ovary | Phase 1 | - | 01 Jun 2015 | |
Clear cell neoplasm of ovary | Phase 1 | - | 01 Jun 2015 |
Phase 2 | 43 | yzrldyskik(nxevineszt) = lfpsmvkrkv axhffjgfwr (emkaquetrt, cmlkyjqonb - yykiowefcy) View more | - | 23 Dec 2022 | |||
Phase 2 | 15 | ipnpljpyov(cfikwfxodb) = cnlpjshlsp rfxvsaouuu (ffwjliniee, bgtxnosjwd - nnziokhttm) View more | - | 15 Nov 2022 | |||
Phase 2 | 12 | uzwpfflsum(xcfnezrsio) = ssarfqyqtq cplfwosjmk (zgauejuidv ) View more | Positive | 13 Feb 2020 | |||
NCT01022138 (ASCO2019) Manual | Phase 2 | Metastatic HER2-Negative Breast Carcinoma HER2-negative | HR Positive | PR Positive | 32 | gziitatpap(jtntplbhnx) = ixdfwqfvhy rglhdusszw (fjezejsosp ) View more | Positive | 02 Jun 2019 | |
(ER/PR+ patients) | gziitatpap(jtntplbhnx) = ezwaptktny rglhdusszw (fjezejsosp ) View more |